{"organizations": [], "uuid": "f72fb58bdfd2a83c102935addf9164af4050647d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "news.morningstar.com", "main_image": "", "site_section": "http://news.morningstar.com/all/dow-jones/technology.aspx", "section_title": "News Archive: Technology", "url": "http://news.morningstar.com/all/dow-jones/technology/201509188910/biomarin-pharmaceutical-dr-reddys-laboratories-settle-patent-suit-over-pku-drug-kuvan.aspx", "country": "US", "title": "BioMarin Pharmaceutical, Dr. Reddy's Laboratories Settle Patent Suit Over PKU Drug Kuvan", "performance_score": 0, "site": "morningstar.com", "participants_count": 1, "title_full": "BioMarin Pharmaceutical, Dr. Reddy's Laboratories Settle Patent Suit Over PKU Drug Kuvan", "spam_score": 0.0, "site_type": "news", "published": "2015-09-18T03:00:00.000+03:00", "replies_count": 0, "uuid": "f72fb58bdfd2a83c102935addf9164af4050647d"}, "author": "morningstar.com", "url": "http://news.morningstar.com/all/dow-jones/technology/201509188910/biomarin-pharmaceutical-dr-reddys-laboratories-settle-patent-suit-over-pku-drug-kuvan.aspx", "ord_in_thread": 0, "title": "BioMarin Pharmaceutical, Dr. Reddy's Laboratories Settle Patent Suit Over PKU Drug Kuvan", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "By Maria Armental\nDrug makers BioMarin Pharmaceutical Inc. and Dr. Reddy's Laboratories Ltd. have agreed to settle a patent dispute over BioMarin's Kuvan's tablets.\nThe drug, sapropterin dihydrochloride, treats phenylketonuria, an inherited genetic disorder diagnosed at birth.\nKuvan, which received marketing approval in the U.S. in 2007, has been designated an orphan drug, which grants market exclusivity for seven years.\nUnder the terms of the agreement reached Sept. 14, BioMarin will grant Dr. Reddy's laboratories a non-exclusive license to allow the Hyderabad, India-based pharmaceutical company to market a generic version of Kuvan 100 mg. tablets in the U.S. for the indications approved for Kuvan \"beginning at a confidential date in the future, but which is more than five years from today, or earlier under certain circumstances.\"\nA similar lawsuit against Par Pharmaceutical Inc. continues.\nWrite to Maria Armental at maria.armental@wsj.com\n 18, 2015 17:46 ET (21:46 ", "external_links": ["http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Checked.gif", "http://s7.addthis.com/static/btn/sm-share-en.gif", "http://www.addthis.com/bookmark.php?v=250", "http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Unchecked.gif"], "published": "2015-09-18T03:00:00.000+03:00", "crawled": "2015-09-19T19:36:36.041+03:00", "highlightTitle": ""}